Immutep Ltd Stock News

The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market. Two FDA approvals came through this week, with Immunomedics, Inc.'s

Immutep reports enrollment completed for INSIGHT-004 study IMMP MKGAY PFE

Immutep Limited's (ASX:IMM): Immutep Limited, a biotechnology company, engages in the research, development, and...

SYDNEY, Australia, April 22, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.

SYDNEY, Australia, April 16, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to announce that Batavia Biosciences, its manufacturing.

Obalon Therapeutics (NASDAQ:OBLN) -25%.NeuroMetrix (NASDAQ:NURO) -16%.Cocrystal Pharma (NASDAQ:COCP) -14%.Covanta Holding (NYSE:CVA) -12% on dividend cut and guidance pull.Independence Contract Dri

SYDNEY, Australia, April 14, 2020 -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plan

Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord

Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus placebo at the 6-month landmarkIncreased Overall Response Rate (ORR) of 48.3%.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), is pleased to report that it has been informed its Chinese partner, EOC Pharma, has completed patient recruitment for the o

Even if it's not a huge purchase, we think it was good to see that Grant Chamberlain, the Non-Executive Director of...

Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancerAIPAC-002 to expedite the possible use of efti for patients in the US SYDNEY, Australia, March 09,.

Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of.